Orion Pharma reports Phase I data from TEADES trial for solid tumours

Orion Pharma Reports Positive Phase I Data for ODM-212 in Solid Tumours

Orion Pharma announced positive Phase I data from its ongoing TEADES trial, evaluating the oral pan-Transcriptional Enhanced Associate Domain (TEAD) inhibitor, ODM-212, in patients with advanced solid tumours. The first-in-human study demonstrated that ODM-212 was well tolerated, with no dose-limiting toxicities or maximum tolerated dose reached. The most common treatment-related adverse event was reversible proteinuria, observed in 19.7% of patients. Preliminary efficacy, assessed by RECIST 1.1, showed an overall response rate of 15.6%. Notably, higher response rates were reported in specific tumour types, including mesothelioma (27.8% ORR) and epithelioid haemangioendothelioma (EHE) (22.2% ORR). The Phase II segment of the TEADES trial is ongoing, aiming to enroll up to 300 patients.

• ODM-212 demonstrated a favorable safety profile in the Phase I TEADES trial, being well tolerated with no dose-limiting toxicities observed and the maximum tolerated dose not reached. The most frequently reported treatment-related adverse event was reversible proteinuria, affecting 19.7% of patients, with 7.9% requiring treatment adjustments. Other common adverse events included increased lipase (15.8%) and nausea (10.5%).
• The trial showed early signs of clinical activity across multiple doses, achieving an overall response rate (ORR) of 15.6% as measured by RECIST 1.1 criteria. This preliminary efficacy data supports the continued investigation of ODM-212 as a potential therapeutic option for advanced solid tumours, indicating its ability to induce tumour responses.
• ODM-212 exhibited particularly encouraging efficacy in certain difficult-to-treat tumour types. Patients with mesothelioma showed a higher overall response rate of 27.8% and a disease control rate of 77.8%. Similarly, patients with epithelioid haemangioendothelioma (EHE) experienced an ORR of 22.2% and a disease control rate of 100%, highlighting the drug's potential in these specific indications where treatment options are limited.
• Following the positive Phase I results, the TEADES trial has progressed to its Phase II segment, which is designed to enroll up to 300 patients. This segment will focus on patients with malignant pleural mesothelioma, EHE, or other solid tumours with Hippo pathway dysfunction who have progressed after standard therapies, further evaluating safety, tolerability, ORR, progression-free survival, and overall survival.

Addressing Unmet Needs in Advanced Solid Tumours

Current treatment approaches for advanced solid tumours face significant limitations that continue to challenge clinical outcomes. Traditional therapies including surgery, radiotherapy, and chemotherapy often fail to completely eradicate tumor cells, leading to disease recurrence and progression with substantial side effects. Despite advances in conventional and targeted agents, cure rates remain disappointing across most common solid tumours in advanced disease stages.

• Incomplete tumor eradication and recurrence risk - Traditional treatments are unable to eliminate all cancer cells, with up to half of breast cancer patients developing refractory or resistant disease despite therapeutic improvements, and recurrence being common in prostate cancer where systemic therapy shows only moderate effectiveness

• Reduced efficacy in challenging tumor environments - The effectiveness of chemotherapy and radiation therapy diminishes significantly in solid tumors, particularly within hypoxic environments that promote immunosuppression and create therapy-resistant conditions

• Off-target toxicity and drug resistance - Cytotoxic chemotherapy frequently causes substantial off-target tissue toxicity while tumors develop multidrug resistance mechanisms, with poor responders to neoadjuvant chemotherapy facing higher risks of relapse and death

• Limited immunotherapy penetration - While immune checkpoint inhibitors and CAR T-cell therapy have transformed outcomes in some cancers, their success has been primarily in hematological malignancies, with solid tumors presenting unique challenges due to immunosuppressive tumor microenvironments

• Acquired resistance to targeted therapies - Kinase inhibitors, despite advancing precision oncology across multiple malignancies, face long-term efficacy constraints from acquired resistance emergence, intratumoral heterogeneity, and off-target toxicities

• Complex resistance pathways - Multiple molecular mechanisms contribute to treatment failure, including TGF-β signaling promoting resistance to chemotherapy and immunotherapy, P-glycoprotein-mediated multidrug resistance, and stress-induced proteasome-mediated degradation of therapeutic targets

TEADES Phase II: Advancing ODM-212 for Specific Solid Tumours

Recent clinical trials in advanced solid tumors demonstrate increasingly sophisticated study designs incorporating biomarker-driven patient selection, combination therapies, and comprehensive endpoint evaluation. These studies span multiple therapeutic modalities from immune checkpoint inhibitors to targeted agents, with emphasis on precision medicine approaches and patient-reported outcomes.

TEAD Inhibition: A New Frontier in Solid Tumor Therapy

The recent announcement of positive Phase I data for Orion Pharma's oral pan-TEAD inhibitor, ODM-212, represents an intriguing step forward in the quest for novel oncology treatments. In the TEADES trial, ODM-212 demonstrated a favorable safety profile, with no dose-limiting toxicities observed and reversible proteinuria as the most common treatment-related adverse event. This early tolerability is crucial for a drug intended for patients with advanced solid tumors.

Beyond safety, the preliminary efficacy signals are noteworthy. An overall response rate of 15.6% was observed, with particularly encouraging results in specific, often challenging, tumor types: 27.8% in mesothelioma and 22.2% in epithelioid haemangioendothelioma (EHE). These findings suggest that TEAD inhibition could offer a new therapeutic avenue for patients with limited options.

Scientifically, the significance of ODM-212 lies in its mechanism of action. As a pan-TEAD inhibitor, it targets the Hippo pathway, which research indicates plays a critical role in the tumor microenvironment. Specifically, dysregulation of the Hippo pathway in cancer-associated fibroblasts (CAFs) has been linked to immunotherapy resistance. By inhibiting TEAD, ODM-212 has the potential to modulate these CAFs, reduce myofibroblast gene expression, and decrease their contractility, thereby potentially overcoming resistance to existing immune checkpoint inhibitors. This opens up strategic possibilities for combination therapies, aiming to enhance responses in a broader patient population.

However, as with all early-stage data, certain considerations remain. The overall response rate, while promising, is modest, and the higher rates in mesothelioma and EHE require further validation in larger cohorts. The occurrence of proteinuria, though reversible, will necessitate careful management and monitoring in subsequent trials. Moving forward, a key challenge will be to precisely identify the patient populations most likely to benefit from TEAD inhibition, perhaps through biomarker-driven approaches focusing on Hippo pathway dysregulation or specific CAF phenotypes. The ongoing Phase II segment of the TEADES trial will be critical in addressing these questions and further solidifying the potential of this novel therapeutic class.